Drug intelligence / Profile preview

[68Ga]Ga-NOTA-5F7

Development stage: Unknown
Lead developer: Fudan University
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-NOTA-5F7 is an investigational radiolabeled single-domain antibody fragment (nanobody) designed for positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2) expression. It consists of the anti-HER2 camelid-derived nanobody 5F7 conjugated to the chelator 1,4,7-triazonane-1,4,7-triacetic acid (NOTA) and labeled with the positron-emitting radionuclide gallium-68 (68Ga). Originally developed at Duke University and clinically translated by Fudan University and Guizhou Medical University, the tracer is being evaluated for non-invasive, whole-body quantification of HER2 expression in patients with HER2-positive breast cancer and metastatic urothelial carcinoma. It demonstrates high sensitivity and potential for detecting intracranial metastases, and is paired with the therapeutic/SPECT agent [131I]SGMIB-5F7 as part of a targeted theranostic strategy.

Other names: 68Ga-NOTA-5F768Ga-NOTA-5F7 PET/CT[68Ga]Ga-NOTA-5F7 PET/CTgallium-68-labeled NOTA-conjugated 5F7 nanobodygallium68-labeled NOTA-conjugated 5F7 nanobodygallium 68-labeled NOTA-conjugated 5F7 nanobodygallium-68-labeled NOTA-conjugated 5F7 single-domain antibody fragmentgallium68-labeled NOTA-conjugated 5F7 single-domain antibody fragmentgallium 68-labeled NOTA-conjugated 5F7 single-domain antibody fragment

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on [68Ga]Ga-NOTA-5F7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-NOTA-5F7.